

Contents

XI Preface
Muenke, M.; Kruszka, P.S. (Bethesda, Md.); Sable, C.A. (Washington, D.C.); Belmont, J.W. (Houston, Tex.)

XIII Foreword
Noonan, J.A. (Lexington, Ky.)

1 Overview

2 Congenital Cardiovascular Anomalies: A Historical Overview

Moller, J.H. (Minneapolis, Minn.)

- 2 Abstract
- 3 Early Descriptions of Anomalies
- 3 Correlating Anatomic and Clinical Features
- 4 Diagnostic Procedures
- 4 Extracardiac Operations
- 6 Intracardiac Operations
- 8 Interventional Catheterization Procedures
- 9 Other Advances
- 9 References

11 Normal Development of the Heart

Sylva, M.; Moorman, A.F.M. (Amsterdam)

- 11 Abstract
- 11 Formation of the Linear Heart Tube
 - 11 Origin of the Cardiac Mesoderm
- 12 Folding of the Embryo and Formation of the Heart Tube
 - 12 Growth of the Linear Heart Tube
 - 15 From One Tube to Four Chambers
 - 15 The Ballooning Model of Chamber Formation
 - 15 Formation of the Atrial Chambers
 - 17 Formation of the Ventricular Chambers
 - 18 Building the ECG
 - 18 The Earliest ECG Recordings

- 18 Sinus Node
- 18 Atrioventricular Node
- 18 Peripheral Ventricular Conduction System
- 19 Septation
 - 19 Atrial Septation
 - 19 Ventricular Septation
 - 19 Septation of the Atrioventricular Canal and Primary Foramen
- 21 Separation of the Outflow Tract
- 21 The Cardiac Connective Tissues
- 21 Development of the Cardiac Vasculature
- 21 The Insulating Plane
- 22 Development of the Valves
- 22 Unidirectional Flow in the Primitive Heart
- 22 The Atrioventricular Valves
- 22 The Semilunar Valves
- 22 Remodeling of the Embryonic Valves
- 22 Future Perspective
- 24 References

2 Epidemiology

28 Epidemiology and Prevention of Congenital Heart Defects

Botto, L.D. (Salt Lake City, Utah)

- 28 Abstract
- 29 Understanding the Problem
- 29 Common, Costly, and Critical: Epidemiology as an Incentive for Action
 - 29 How Common Are Congenital Heart Defects?
 - 30 What Drives the Variations in Reported Birth Prevalence?
- 32 How Many People Are Living with Congenital Heart Defects – Including Adults?
- 32 How Costly Are Congenital Heart Defects?
- 33 Short-Term Assessment: Cross-Sectional Costs

34	Long-Term View: Lifetime Costs	72	Cardiac Failure
34	How Critical Are Heart Defects?	73	Arrhythmias
34	Prevention: Evidence and Strategies	74	Pulmonary Hypertension
35	Integrating Interventions	75	Pregnancy and Delivery
35	When to Start Preventing?	76	Psychosocial Issues
35	What Proportion of Heart Defects Can Be Prevented?	76	Possibility of Acquired Cardiovascular Disease
36	Estimating How Many Cases Can Be Prevented	77	Aortopathy
37	Maximizing the Impact	77	Conclusion
38	Case Study: Maternal Diabetes	78	References
39	Case Study: Folic Acid/Multivitamins		
40	Putting Everything Together: Healthy Heart, Healthy Child, and Healthy Parents		
41	Epidemiology and Prevention: Trends and Future		
43	Conclusions		
43	References		
46	Clinical Epidemiology and Management of Congenital Heart Defects in a Developing Country		
	Ekure, E.N. (Lagos); Adeyemo, A.A. (Bethesda, Md.)		
46	Abstract	82	Abstract
47	Types of Congenital Heart Defects Seen in Nigeria	82	Epidemiology
49	Etiology of Congenital Heart Defects in Nigeria	83	Genetics
50	Age at Diagnosis	84	Embryogenesis
51	Clinical Presentation	85	Clinical Presentation
52	Management of Congenital Heart Defects in Nigeria	85	Cardiac Phenotype
54	Outcome	87	Treatment
54	Challenges and Opportunities	88	Prognosis
55	References	88	Gene Therapy for Future Directions
55		88	References
57	Maternal Nongenetic Risk Factors for Congenital Heart Defects		
	Riehle-Colarusso, T.J. (Atlanta, Ga.); Patel, S.S. (Aurora, Colo.)		
57	Abstract	91	Abstract
58	Understanding Risk Factors for Congenital Heart Defects	92	Spectrum of Congenital Cardiovascular Malformations in Turner Syndrome
58	Measurements of Associations for Risk Factors with Congenital Heart Defects	92	Aortic Valve
59	Challenges of Studying Risk Factors for Congenital Heart Defects	93	Aortic Dilatation
59	Select Risk Factors	93	Aortic Arch
60	Maternal Sociodemographic Characteristics	94	Partial Anomalous Pulmonary Venous Return
60	Maternal Health Conditions	94	Other Cardiovascular Defects
65	Maternal Therapeutic Medications	94	Theories on the Cause of Congenital Cardiovascular Defects in Turner Syndrome
66	Maternal Nontherapeutic Drugs	94	Association with Fetal Lymphedema
66	Conclusion	95	Neural Crest
67	References	95	Parallels with the 22q11.2 Deletion (DiGeorge Syndrome)
70	Adults with Congenital Heart Disease	96	Genes Implicated in Turner Syndrome
	Niwa, K. (Tokyo)	97	X-Chromosome Genomic Imprinting
70	Abstract	97	Conclusion
70	Frequency of Adult Congenital Heart Disease	97	References
71	Treatment Facilities and Human Resources		
72	Current Status and Future Prospects of Adult Congenital Heart Disease		
72	Common Problems and Specific Pathophysiological Issues in Adult Congenital Heart Disease	100	The 22q11.2 Deletion Syndrome
			Goldmuntz, E. (Philadelphia, Pa.)
100	Abstract	100	Abstract
101	Molecular Characteristics of the 22q11.2 Deletion Syndrome	101	Molecular Characteristics of the 22q11.2 Deletion Syndrome
101	Clinical Characteristics of the 22q11.2 Deletion Syndrome	101	Congenital Heart Disease in the 22q11.2 Deletion Syndrome

3 Chromosomal Disorders

82 Down Syndrome

Kruszka, P.S. (Bethesda, Md.)

82	Abstract
82	Epidemiology
83	Genetics
84	Embryogenesis
85	Clinical Presentation
85	Cardiac Phenotype
87	Treatment
88	Prognosis
88	Gene Therapy for Future Directions
88	References

91 Congenital Cardiovascular Defects in Monosomy X or Turner Syndrome

Bondy, C. (Bethesda, Md.)

91	Abstract
92	Spectrum of Congenital Cardiovascular Malformations in Turner Syndrome
92	Aortic Valve
93	Aortic Dilatation
93	Aortic Arch
94	Partial Anomalous Pulmonary Venous Return
94	Other Cardiovascular Defects
94	Theories on the Cause of Congenital Cardiovascular Defects in Turner Syndrome
94	Association with Fetal Lymphedema
95	Neural Crest
95	Parallels with the 22q11.2 Deletion (DiGeorge Syndrome)
96	Genes Implicated in Turner Syndrome
97	X-Chromosome Genomic Imprinting
97	Conclusion
97	References

100 The 22q11.2 Deletion Syndrome

Goldmuntz, E. (Philadelphia, Pa.)

100	Abstract
101	Molecular Characteristics of the 22q11.2 Deletion Syndrome
101	Clinical Characteristics of the 22q11.2 Deletion Syndrome
101	Congenital Heart Disease in the 22q11.2 Deletion Syndrome

103	Noncardiac Manifestations of the 22q11.2 Deletion Syndrome	131	The Holt-Oram Syndrome and Other Transcription Factor-Related Heart Diseases
104	The 22q11.2 Deletion Syndrome and Congenital Heart Disease		Borlak, J. (Hannover); Ciribilli, Y. (Mattarello)
104	22q11.2 Deletions in Conotruncal Defects	131	Abstract
105	Identifying the Cardiac Patient with a 22q11.2 Deletion	131	The Holt-Oram Syndrome
106	Clinical Outcome	132	Transcription Factors and Embryogenesis
108	Clinical Management of the Cardiac Patient with a 22q11.2 Deletion	134	Germline Mutations
108	References	136	Somatic Mutations
112	Other Genomic Disorders Causing Congenital Cardiovascular Malformations	138	Gene Reporter Assays to Evaluate the Clinical Significance of Mutations
	Lalani, S.R. (Houston, Tex.)	139	'Isogenic Nature'
112	Abstract	140	'Chromatin Environment'
114	Genomic Rearrangements	140	'Reporter Constructs'
114	Copy Number Variations in Congenital Cardiovascular Malformations	141	'Rheostatable Promoters'
115	1p36 Deletion	141	'Mutant Protein Assays'
115	8p23.1 Deletion/Duplication	142	Conclusion
115	Williams-Beuren Syndrome	142	References
115	Kleefstra Syndrome		
116	Smith-Magenis Syndrome/Potocki-Lupski Syndrome	145	CHARGE Syndrome
116	Koolen-de Vries Syndrome		Corsten-Janssen, N.; van Ravenswaaij-Arts, C.M.A. (Groningen)
116	Wolf-Hirschhorn Syndrome	145	Abstract
117	Jacobsen Syndrome	146	Diagnosis
117	Other Genomic Rearrangements	146	Clinical Diagnosis
117	Less Frequent CVM-Associated Genomic Disorders	147	Molecular Diagnosis
118	Conclusion	148	Other Causes of the CHARGE Syndrome
118	References	149	Broad Phenotypic Spectrum of CHD7 Mutations
		149	Clinical Features of Patients with a CHD7 Mutation
		149	CHD7 Mutations in Other Syndromes
		149	Genotype-Phenotype Associations
		150	Heart Defects in the CHARGE Syndrome
		151	CHD7 Function in the Heart
		152	Clinical Surveillance and Genetic Counseling
		152	Concluding Remarks
		153	References
122	Noonan Syndrome and Other RAS/MAPK Pathway Syndromes	155	Alagille Syndrome
	Gelb, B.D. (New York, N.Y.); Roberts, A.E. (Boston, Mass.); Tartaglia, M. (Rome)		Lin, H.C.; Falsey, A.; Krantz, I.; Spinner, N. (Philadelphia, Pa.)
122	Abstract	155	Abstract
123	RASopathy-Associated Cardiovascular Involvement	156	Pathophysiology
123	The Noonan Syndrome	156	Clinical Features
125	The Noonan Syndrome with Multiple Lentigines	157	Hepatic Manifestations
125	The Cardiofaciocutaneous Syndrome	158	Cardiac Manifestations
125	The Costello Syndrome	159	Musculoskeletal Manifestations
126	The Noonan Syndrome with Loose Anagen Hair	159	Ocular Manifestations
126	RASopathy Genetics	160	Facial Features
127	Genotype-Phenotype Associations	160	Renal Manifestations
127	Pathogenesis of Cardiovascular Disease in the RASopathies	161	Vascular Manifestations
127	The Noonan Syndrome	161	Cognitive Function
128	The Noonan Syndrome with Multiple Lentigines	161	Diagnosis
128	The Costello Syndrome	162	Management
128	Concluding Remarks	163	Genetic Counseling
128	Acknowledgments	163	Conclusion
128	References	163	References

166	Heterotaxy	191	The Rubinstein-Taybi Syndrome
	Lo, C.; Li, Y.; Yagi, H.; Gabriel, G.; Klena, N.; Lemke, K. (Pittsburgh, Pa.); Leatherbury, L. (Washington, D.C.)	192	Diagnosis/Evaluation
166	Abstract	192	The Char Syndrome
168	Classification of Heterotaxy: Atrial Isomerisms and Other Laterality Defects	193	Diagnosis/Evaluation
169	Association of Complex Congenital Heart Disease with Heterotaxy	193	The Goldenhar Syndrome
169	Left-Right Patterning and Regulation of Cardiac Looping	193	Diagnosis/Evaluation
171	Genetic Etiology of Heterotaxy	193	Conclusion
171	Ciliopathies and Heterotaxy	193	Acknowledgments
172	Airway Cilium Dysfunction Associated with Primary Ciliary Dyskinesia and Heterotaxy	194	References
172	Respiratory Symptoms and Disease in Ciliopathy and Heterotaxy Patients		
173	Respiratory Complications and Worse Outcome in Heterotaxy Patients		
173	Summary and Future Prospects for Improving Clinical Care and Outcome		
175	Acknowledgments		
175	References		
178	Molecular Genetics of Isolated Cardiovascular Malformations	198	Genetic Arrhythmias (Channelopathies)
	Lee, T.M.; Chung, W.K. (New York, N.Y.)		Mazzanti, A.; Ng, K. (Pavia); Priori, S.G. (Pavia/New York, N.Y.)
178	Abstract	198	Abstract
179	Monogenic Cardiovascular Malformations	199	Long QT Syndrome
179	Atrial Septal Defects	199	Epidemiology
181	Ventricular Septal Defects	199	Genetic Variants
181	Bicuspid Aortic Valves	199	Diagnosis
181	Supravalvar Aortic Stenoses	201	Clinical Manifestations
181	Additional Lesions	201	Risk Stratification
182	Recent Advances	202	Management
182	Copy Number Variants	202	Short QT Syndrome
182	De novo Variants	202	Epidemiology
182	Genome-Wide Association Studies	202	Genetic Variants
182	Clinical Genetic Evaluation and Testing	203	Diagnosis
183	Conclusion	203	Clinical Manifestations
183	References	203	Risk Stratifications and Management
186	Other Single-Gene Disorders Causing Congenital Heart Disease	204	Brugada Syndrome
	Russell, M.W.; Hannibal, M. (Ann Arbor, Mich.)	204	Epidemiology
186	Abstract	204	Genetic Variants
186	VACTERL Association	204	Diagnosis
187	Diagnosis/Evaluation	204	Clinical Manifestations
187	The Kabuki Syndrome	205	Risk Stratification
188	Diagnosis/Evaluation	205	Management
188	The Ellis-van Creveld Syndrome	206	Catecholaminergic Polymorphic Ventricular Tachycardia
189	Diagnosis/Evaluation	206	Epidemiology
189	The Cornelia de Lange Syndrome	206	Genetic Variants
190	Diagnosis/Evaluation	206	Diagnosis
190	The Mowat-Wilson Syndrome	207	Clinical Manifestations
190	Diagnosis/Evaluation	207	Risk Stratifications
190	The Smith-Lemli-Opitz Syndrome	207	Management
191	Diagnosis/Evaluation	208	Conclusions
191	Treatment	208	References
210	Genetic Cardiomyopathies		
	Towbin, J.A. (Memphis, Tenn.)		
210	Abstract		
211	Final Common Pathways		
211	Dilated Cardiomyopathy		
212	Genetics of Dilated Cardiomyopathy		
216	Muscle Is Muscle: Cardiomyopathy and Skeletal Myopathy Genes Overlap		
216	Hypertrophic Cardiomyopathy		

216	Gene Identification in Familial Hypertrophic Cardiomyopathy	262	Ventricular Septal Defects
217	Genotype-Phenotype Correlation in Hypertrophic Cardiomyopathy	264	Atrioventricular Septal Defects
218	Restrictive Cardiomyopathy	265	Tetralogy of Fallot
218	Genetics	266	Pulmonary Valve Stenosis
218	Left-Ventricular Noncompaction Cardiomyopathy	267	Concluding Remarks
219	Genetics	268	References
220	Arrhythmogenic Cardiomyopathies	269	Prenatal Evaluation of Congenital Heart Defects and Fetal Intervention
220	Genetics		Weinberg, J.G.; Krishnan, A. (Washington, D.C.)
222	Conclusions	269	Abstract
222	References	269	Indications for Fetal Cardiac Evaluation
226	Congenital Thoracic Aortic Aneurysm	270	Timing and Performance of Fetal Echocardiography
	Lindsay, M.E. (Boston, Mass.); Dietz, H.C. (Baltimore, Md.)	271	Prenatal Diagnosis of Congenital Heart Defects Associated with Specific Genetic Defects
226	Abstract	271	Fetal Intervention
227	Gene Discovery	275	Importance of Fetal Diagnosis and Outcomes following Prenatal Detection of Congenital Heart Defects
229	Inheritance and Genetic Counseling	276	References
230	Clinical Findings and Diagnoses		
232	Management and Molecular Pathogenesis		
233	Conclusions		
234	References		

6 Evaluation

238	The Genetic Workup for Congenital Structural Heart Disease: From Clinical to Genetic Evaluation
	Kruszka, P.S. (Bethesda, Md.); Sable, C.A. (Washington, D.C.); Belmont, J.W. (Houston, Tex.); Muenke, M. (Bethesda, Md.)
238	Abstract
240	Genetic Testing Algorithm
248	Aneuploidy
248	Copy Number and Structural Variants
250	Targeted Gene Sequencing
252	Whole Genome and Whole Exome Sequencing
254	Genetic Counseling
254	Concluding Remarks
254	References
257	Imaging of Congenital Heart Defects for the Noncardiologist
	Sable, C.A. (Washington, D.C.)
257	Abstract
257	Types of Imaging
257	Ultrasound Physics
259	Echocardiography Examination
260	Echocardiography Logistics: Why, When, Where, Who . . . Indications
260	Timing of Imaging
260	Where/Who Does the Echocardiography
261	Common Lesions
261	Atrial Septal Defects

7 Treatment

280	Surgical Management
	Costello, J.P.; Jonas, R.A.; Nath, D.S. (Washington, D.C.)
280	Abstract
280	Trisomy 21 – Down Syndrome
283	The 22q11.2 Deletion – DiGeorge Syndrome
284	Trisomy 13 (Patau Syndrome) and Trisomy 18 (Edwards Syndrome)
285	Marfan Syndrome
285	Turner Syndrome
285	Noonan Syndrome
286	Other Syndromes
286	Special Considerations
287	References
289	Interventional Cardiology
	Morgan, G.J.; Qureshi, S.A. (London)
289	Abstract
289	Interventional Cardiac Catheterisation in Paediatric Cardiology
289	Neonatal Intervention
290	Atrial Septostomy
290	Aortic Valvoplasty
291	Pulmonary Valvoplasty
292	Infant and Paediatric Procedures
292	Atrial Septal Defect Occlusion
293	Ventricular Septal Defect Occlusion
294	Transcatheter Pulmonary Valve Implantation
294	Coarctation Stent Implantation
295	Stent Technology
295	Fetal Interventions
295	Hybrid Techniques
296	Hybrid Palliation of Hypoplastic Left Heart Disease
296	Muscular Ventricular Septal Defect Closure
297	Paravalvar Leak Occlusion

297	Conclusion	307	Tissue-Forming Cell Population
297	References	308	Mechanical Load and Electrical Stimulation
298	Ethical Considerations in Congenital Heart Disease	308	Bioreactors – A Breeding Ground for Engineered Heart Tissue
	Boss, R.D.; Shapiro, M.C. (Baltimore, Md.)	309	Current Challenges for Engineered Heart Tissue Production
298	Abstract	309	Cardiomyocyte Maturation
299	Social Justice and Congenital Heart Disease Risk	310	Host Immune Response
299	Prenatal Diagnosis: Promises and Harms	310	Ischemia within Engineered Heart Tissue
300	A Life Worth Living – Can We Agree?	310	Decellularized Heart as an Artificial Scaffold for Engineered Heart Tissue
301	Survivors of Congenital Heart Disease and Demand for Destination Therapies	311	Stem Cells in Engineered Heart Tissue
302	Palliative Care – Clinicians' Personal Choices versus Professional Recommendations	312	Reentry of Mature Cardiomyocytes into the Cell Cycle
303	Conclusions	313	Novel Possibilities for Treating Hypertrophic Cardiomyopathy
303	References	313	Gene Therapy as Early Intervening Strategies
306	The Future of Therapeutics: Stem Cells, Tissue Plasticity, and Tissue Engineering	314	Perspectives
	Tao, G.; Martin, J.F. (Houston, Tex.)	314	References
306	Abstract	317	Author Index
306	Cardiac Tissue Engineering	318	Subject Index
307	Supportive Matrix in Favor of Tissue Formation		